SNAP-Tag-Based Antibody-Drug Conjugates Targeting Epidermal Growth Factor Receptor 1, Epidermal Growth Factor Receptor 2, Trophoblast Cell-Surface Antigen 2, and Tissue Factor for Ovarian Cancer Treatment. This evidence concerns the gene F3 and ovarian carcinoma.